The programme will be led by a board of Directors who will provide Fellows with diverse perspectives.
Professor Chris Ponting
Prof Chris Ponting is a Professor of Medical Bioinformatics at the University of Edinburgh, and the Director of Data Innovation at the Institute for Genetics and Molecular Medicine.
Prof Ponting leads the XDF Programme. He was trained first in particle physics before pursuing a successful career in biomedicine, so knows first-hand the skills necessary for Fellows to transition into “Big Data Biomedicine”. He was Chair of the MRC Bioinformatics Training Panel, Founding Director of the MRC CGAT Training Centre, and jointly led the ELIXIR European Training Platform. His research is in computational and experimental genomics, specifically on the molecular and genetic mechanisms of disease, and he has recruited individuals with diverse backgrounds, from physics and computer science, to biology and biochemistry, to his research group.
Professor Jane Hillston
Prof Jane Hillston is a Professor of Quantitative Modelling at the University of Edinburgh, she is also the Director of Research and Deputy Head of School in the School of Informatics, and from the 1st August will assume the role of the Head of School in Informatics.
Prof Hillston gained a BA in Mathematics from the University of York, UK in 1985 and an MS in Mathematics from Lehigh University, USA in 1987. After a short spell in industry, she studied for a PhD in Computer Science at the University of Edinburgh, which was awarded in 1994. She was appointed Professor of Quantitative Modelling in the School of Informatics at the University of Edinburgh in 2006, having joined the University as a Lecturer in Computer Science in 1995.
Jane Hillston’s research is concerned with formal approaches to modelling dynamic behaviour, particularly for performance modelling and stochastic verification. Her PhD dissertation was awarded the BCS/CPHC Distinguished Dissertation award in 1995 and she was the first recipient of the Roger Needham Award in 2005. She held an EPSRC Advanced Research Fellowship 2001-2010. She has published over 100 journal and conference papers and held several Research Council and European Commission grants. She is a fellow of the BCS and the Royal Society of Edinburgh.
Professor Guido Sanguinetti
Prof Guido Sanguinetti is a Professor of Computational Bioinformatics at the University of Edinburgh.
Prof Sanguinetti obtained MSc in physics and DPhil in mathematics. His research group is part of the Institute of Adaptive and Neural Computation, within the School of Informatics. His general interests lie in the development of machine learning techniques to address challenges in scientific modelling. He has published over 80 publications in international journals and conferences including Science, Nature Methods, PNAS. He has supervised thirteen PhD students and served as external examiner in over 15 Universities in the UK, Germany, Italy, Sweden and Finland. He held an ERC Starting Grant 2012-17 and was the recipient of the 2012 PNAS Cozzarelli Award in Engineering and Applied Sciences, as well as several other best paper awards. He served as area chair for the International Conference on Machine Learning, the European Conference on Machine Learning, and is a steering committee member of the community of special interest on Machine Learning in Computational Systems Biology within the International Society for Computational Biology. He served on the Informatics Equality and Diversity Committee since its inception and formed part of the self-assessment team for the School's two successful Athena Swann Silver Award submissions.
Professor Margaret Frame
Prof Margaret Frame (OBE) is a Professor of Cancer Research at the University of Edinburgh and the Director of the MRC Institute of Genetics and Molecular Medicine.
Prof Frame has a background in biochemistry and molecular pathology. Her research focuses on protein networks biology and functions of cell-adhesion proteins in the context of cancer. A key feature of her lab’s work during the recent past has been to embrace inter-disciplinary team science that brings new innovative approaches to cancer biology questions. The overarching aims of her research are: (i) mapping cancer phenotypes on to cancer pathways, using mouse- and human patient-derived material as biological source; and (ii) to improve the predictivity of pre-clinical therapeutic testing. She has a special interest in inter-disciplinary doctoral and post-doctoral training, and the support and mentoring of all early- and mid-career researchers.
She serves (or served) on multiple decision-making bodies and in other advisory/management roles. Current and past examples include: President of the British Association for Cancer Research (BACR; from Jan 2016); AACR/CRUK – “Stand Up For Cancer“: panel 2014; European Research Council (ERC) Starter grants panel : sub-panel LS3; Chair: Academy of Medical Sciences, Genetics, Cellular and Developmental Biology, Microbiology and Immunology Panel; Royal Society of Edinburgh, Cell and Molecular Biology Panel; Chair: Cancer Research UK (CR-UK), New Investigator Panel; Cancer Research UK, Training and Career Development Board; Cancer Research UK, Science Strategy Advisory Group; Cross UK-North America Cancer Imaging Alliance – joint initiative between CR-UK, NCI-USA and Canadian Institutes of Health Research’s Institute of Cancer Research (CIHR-ICR); Wellcome Trust, Genes, Molecules and Cells Panel; Advisory/Review Boards for several European Institutions: Oslo Centre for Biotechnology, University of Basel, Department of Biomedizine, Karolinska Institute Cancer Appointments Advisory Board, FP7 ‘Molecular Oncology Pathways’ Turin Advisory Board, Marseilles Institute of Biology, France, Bristol Myers Squibb, Europe and USA; membership in several University of Edinburgh (UoE) committees (including: Institute of Genetics and Molecular Medicine (IGMM) Executive, IGMM Science Translational Strategy Group (Chair), CRUK Edinburgh Centre Governance Board, College of Medicine and Veterinary Medicine (CMVM) Strategy Group, UoE: Research Planning Group).
Professor Tim Aitman
Prof Aitman is a Professor of Molecular Pathology and Genetics at the University of Edinburgh. He is the Director of the Centre for Genomic and Experimental Medicine within the MRC Institute of Genetics and Molecular Medicine, Clinical Director of the HiSeq X genome sequencing facility in Edinburgh Genomics and Consultant Physician in NHS Lothian.
Prof Aitman trained in both physiology/biochemistry and medicine. His research uses genome technology and information to elucidate the genetic basis of both common and rare human disorders and to relate genotype and epigenotype to phenotype. Increasingly, the challenge is to use large datasets - genetic, epigenetic, genomic and phenotypic - to diagnose and stratify human disease, and to use advances in these areas to move research findings towards routine healthcare. Clinical areas of interest include rare Mendelian disorders and cancer. Wet lab approaches include high-throughput sequencing and bespoke quantitative assays of somatic mutation and DNA methylation. In silico approaches include mining of large public and host-generated datasets, computational modelling of disease states and integration of multiple data modalities to understand and manage human disease.
Prof Aitman is a Fellow of the Royal Society of Edinburgh, the Royal College of Physicians, the Academy of Medical Sciences, and the Society of Biology. He is currently co-Director and Edinburgh PI of the Scottish Genomes Partnership, a nationally important collaboration with the NHS, and is also Director of the Edinburgh-St Andrews Consortium for Molecular Pathology, Informatics and Genome Sciences, one of only six MRC-EPSRC Molecular Pathology Nodes in the UK.
Professor Ian Tomlinson
Prof Tomlinson is Director of the Edinburgh Cancer Research Centre (including CRUK Edinburgh Centre), and Charles and Ethel Barr Chair of Cancer Research.
Prof Tomlinson was previously Director of the Institute of Cancer and Genomic Sciences at the University of Birmingham, having worked before that at the Cancer Research UK London Research Institute, University of Oxford and the Institute of Cancer Research. His research interests lie in discovering and functionally characterising cancer driver genes, especially germline variants that predispose to cancer. He also has a longstanding interest in cancer evolution, derived from his PhD project in population genetics, with a specific interest in the relative contributions of selection and mutation to cancer growth. Ian's work focuses on colorectal cancer, but extends to several other cancer types. He is especially keen to integrate work across a variety of biomedical areas, including human patient cohorts and clinics, animal models of disease and biomathematics.